Tag: Hatch-Waxman Act
Generic drugs saved the U.S. healthcare system $3.4 trillion from 2015-2024. Learn how Hatch-Waxman, biosimilars, and market competition drive these massive savings and what challenges remain.
Explore how the FDA approves generic drugs via the ANDA process, ensuring safety and savings. Learn about bioequivalence standards, GDUFA timelines, and the impact of the Hatch-Waxman Act on your medication.
Medications
Archives
Recent-posts
Genetic Factors That Increase Susceptibility to Drug Side Effects
Dec, 20 2025
Top 5 Metformin Alternatives in 2025 for Diabetes Management
Jan, 5 2025
Therapeutic Drug Monitoring for Generic NTIs: Protecting Patients on Antiretroviral Therapy
Feb, 26 2026
Top Priligy Alternatives in 2024 for Enhanced Sexual Health
Oct, 3 2024
How Pharmacists Are Leading the Charge in Immunizations and Generic Prescriptions
Dec, 1 2025